Evidence map›Paper›PMID 33229401›Full record

ArticleMolecular cancer research : MCR2021

Characterization of Clonal Evolution in Microsatellite Unstable Metastatic Cancers through Multiregional Tumor Sequencing.

Russell Bonneville, Anoosha Paruchuri, Michele R Wing, Melanie A Krook, Julie W Reeser, Hui-Zi Chen, Thuy Dao, Eric Samorodnitsky, Amy M Smith, Lianbo Yu and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Russell BonnevilleComprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Anoosha ParuchuriComprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Michele R WingComprehensive Cancer Center, The Ohio State University, Columbus, Ohio.ORCID https://orcid.org/0000-0001-9688-0396
Melanie A KrookComprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Julie W ReeserComprehensive Cancer Center, The Ohio State University, Columbus, Ohio.ORCID https://orcid.org/0000-0003-1113-0014
Hui-Zi ChenComprehensive Cancer Center, The Ohio State University, Columbus, Ohio.ORCID https://orcid.org/0000-0002-9028-622X
Thuy DaoComprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Eric SamorodnitskyComprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Amy M SmithComprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Lianbo YuDepartment of Biomedical Informatics, The Ohio State University, Columbus, Ohio.
Nicholas NowackiDepartment of Pathology, The Ohio State University, Columbus, Ohio.
Wei ChenDepartment of Pathology, The Ohio State University, Columbus, Ohio.ORCID https://orcid.org/0000-0002-9028-622X
Sameek RoychowdhuryComprehensive Cancer Center, The Ohio State University, Columbus, Ohio. sameek.roychowdhury@osumc.edu.
The Ohio State University · US

Funding

Integrative Training in Biomedical SystemsT32GM068412 · NIGMS · OHIO STATE UNIVERSITY · PI PARVIN, JEFFREY D · 2005 to 2020
$2.4M
NRSA Training CoreTL1TR002735 · NCATS · OHIO STATE UNIVERSITY · PI BUMGARDNER, GINNY L, KIRSCHNER, LAWRENCE S · 2018 to 2022
$1.3M
Genomic characterization of tumor heterogeneity in recurrent small cell lung cancer through research autopsyK08CA241309 · NCI · OHIO STATE UNIVERSITY · PI CHEN, HUI-ZI · 2019 to 2023
$1.2M
Detection of microsatellite instability biomarkers for therapeutic clinical trial eligibilityUH3CA216432 · NCI · OHIO STATE UNIVERSITY · PI ROYCHOWDHURY, SAMEEK · 2019 to 2021
$942k
Detection of microsatellite instability biomarkers for therapeutic clinical trial eligibilityUH2CA216432 · NCI · OHIO STATE UNIVERSITY · PI ROYCHOWDHURY, SAMEEK · 2017 to 2017
$354k
Assay Validation of Targeted RNA sequencing to Detect Kinase Gene FusionsUH2CA202971 · NCI · OHIO STATE UNIVERSITY · PI ROYCHOWDHURY, SAMEEK · 2016 to 2016
$352k
NCATS NIH HHS TL1 TR002735NCI NIH HHS K08 CA241309NCI NIH HHS UH2 CA202971NCI NIH HHS UH2 CA216432NCI NIH HHS UH3 CA216432NIGMS NIH HHS T32 GM068412
6 · The paper itself

Abstract

Microsatellites are short, repetitive segments of DNA, which are dysregulated in mismatch repair-deficient (MMRd) tumors resulting in microsatellite instability (MSI). MSI has been identified in many human cancer types with varying incidence, and microsatellite instability-high (MSI-H) tumors often exhibit increased sensitivity to immune-enhancing therapies such as PD-1/PD-L1 inhibition. Next-generation sequencing (NGS) has permitted advancements in MSI detection, and recent computational advances have enabled characterization of tumor heterogeneity via NGS. However, the evolution and heterogeneity of microsatellite changes in MSI-positive tumors remains poorly described. We determined MSI status in 6 patients using our previously published algorithm, MANTIS, and inferred subclonal composition and phylogeny with Canopy and SuperFreq. We developed a simulated annealing-based method to characterize microsatellite length distributions in specific subclones and assessed the evolution of MSI in the context of tumor heterogeneity. We identified three to eight tumor subclones per patient, and each subclone exhibited MMRd-associated base substitution signatures. We noted that microsatellites tend to shorten over time, and that MMRd fosters heterogeneity by introducing novel mutations throughout the disease course. Some microsatellites are altered among all subclones in a patient, whereas other loci are only altered in particular subclones corresponding to subclonal phylogenetic relationships. Overall, our results indicate that MMRd is a substantial driver of heterogeneity, leading to both MSI and subclonal divergence. IMPLICATIONS: We leveraged subclonal inference to assess clonal evolution based on somatic mutations and microsatellites, which provides insight into MMRd as a dynamic mutagenic process in MSI-H malignancies.

Indexed as

Microsatellite InstabilityAdultAgedAged, 80 and overClonal EvolutionFemaleGenomicsHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedNeoplasm Metastasis

Identifiers

PMID33229401
PMCPMC7939074
OpenAlexW3110375522

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.